JP2023549455A - 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用 - Google Patents

脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用 Download PDF

Info

Publication number
JP2023549455A
JP2023549455A JP2023524333A JP2023524333A JP2023549455A JP 2023549455 A JP2023549455 A JP 2023549455A JP 2023524333 A JP2023524333 A JP 2023524333A JP 2023524333 A JP2023524333 A JP 2023524333A JP 2023549455 A JP2023549455 A JP 2023549455A
Authority
JP
Japan
Prior art keywords
sma
apitegromab
patient
therapy
smn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549455A5 (cg-RX-API-DMAC10.html
Inventor
ジョージ ノミコス
グオチェン ソン
ライアン イアロビノ
ユン チョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of JP2023549455A publication Critical patent/JP2023549455A/ja
Publication of JP2023549455A5 publication Critical patent/JP2023549455A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023524333A 2020-10-26 2021-10-25 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用 Pending JP2023549455A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US63/105,850 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US63/106,172 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US63/200,955 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US63/201,157 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US63/202,317 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US63/202,372 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US63/202,900 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US63/260,725 2021-08-30
US202163261398P 2021-09-20 2021-09-20
US63/261,398 2021-09-20
PCT/US2021/056517 WO2022093724A1 (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
JP2023549455A true JP2023549455A (ja) 2023-11-27
JP2023549455A5 JP2023549455A5 (cg-RX-API-DMAC10.html) 2024-10-10

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524333A Pending JP2023549455A (ja) 2020-10-26 2021-10-25 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用

Country Status (13)

Country Link
US (1) US20240002490A1 (cg-RX-API-DMAC10.html)
EP (2) EP4232151B1 (cg-RX-API-DMAC10.html)
JP (1) JP2023549455A (cg-RX-API-DMAC10.html)
KR (1) KR20230095998A (cg-RX-API-DMAC10.html)
CN (1) CN116390756A (cg-RX-API-DMAC10.html)
AU (1) AU2021369471A1 (cg-RX-API-DMAC10.html)
CA (1) CA3193909A1 (cg-RX-API-DMAC10.html)
ES (1) ES3058087T3 (cg-RX-API-DMAC10.html)
IL (1) IL302132A (cg-RX-API-DMAC10.html)
MX (1) MX2023004763A (cg-RX-API-DMAC10.html)
PL (1) PL4232151T3 (cg-RX-API-DMAC10.html)
TW (1) TW202233234A (cg-RX-API-DMAC10.html)
WO (1) WO2022093724A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
LT4518970T (lt) 2022-05-04 2026-04-27 Scholar Rock, Inc. Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2026076383A1 (en) 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy
EP4763222A1 (en) * 2025-08-25 2026-06-24 Qilu Pharmaceutical Co., Ltd. A composition comprising apitegromab

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523295A (ja) * 2016-06-13 2019-08-22 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ミオスタチン阻害剤の使用および併用療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523295A (ja) * 2016-06-13 2019-08-22 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ミオスタチン阻害剤の使用および併用療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLACE, A. ET AL.: "A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal M", EUROPEAN JOURNAL OF NEUROLOGY, vol. Vol.27, suppl.1, JPN6025041119, May 2020 (2020-05-01), pages 103 - 522, ISSN: 0005833041 *

Also Published As

Publication number Publication date
CA3193909A1 (en) 2022-05-05
CN116390756A (zh) 2023-07-04
WO2022093724A1 (en) 2022-05-05
TW202233234A (zh) 2022-09-01
EP4232151A1 (en) 2023-08-30
EP4729069A1 (en) 2026-04-22
MX2023004763A (es) 2023-05-09
IL302132A (en) 2023-06-01
PL4232151T3 (pl) 2026-02-23
ES3058087T3 (en) 2026-03-06
US20240002490A1 (en) 2024-01-04
KR20230095998A (ko) 2023-06-29
AU2021369471A1 (en) 2023-06-15
AU2021369471A9 (en) 2024-02-08
EP4232151B1 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
AU2021261907B2 (en) Use of myostatin inhibitors and combination therapies
EP4232151B1 (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
CN119451696A (zh) 肌生成抑制蛋白抑制剂用于治疗脊髓性肌肉萎缩的用途
US20240358704A1 (en) Combined administration
EA051098B1 (ru) Применение антитела к промиостатину/латентному миостатину для лечения спинальной мышечной атрофии
HK40100646A (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
HK40100646B (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
WO2026076383A1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
HK40097101A (en) Use of myostatin inhibitors and combination therapies
HK40043422A (en) Use of myostatin inhibitors and combination therapies
HK1260302A1 (en) Use of myostatin inhibitors and combination therapies
HK1260302B (en) Use of myostatin inhibitors and combination therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260626

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260724

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260729